Bausch + Lomb (BLCO) will pay $1.75B to acquire a dry-eye drug Xiidra from Novartis (NVS), people familiar with the matter told The Wall Street Journal’s Jared Hopkins. The sources said the companies could announce the agreement as early as Friday, the report noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BLCO: